Skip to main content

Table 1 Clinicopathologic characteristics of patients with stage 2 and 3 gastric cancer

From: Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study

Variables Whole patients (N = 958) Recurrence group (N = 293) Non-recurrence group (N = 665) P-value
Mean age at operation, years (±SD) 57.0 (±12.3) 57.7 (±12.6) 56.7 (±12.2) 0.240
Sex     0.449
 Male 624 (65.1%) 196 (66.9%) 428 (64.4%)  
 Female 334 (34.9%) 97 (33.1%) 237 (35.6%)  
Comorbidity     0.763
 Diabetes 138 (14.4%) 44 (15.0%) 94 (14.1%)  
 Hypertension 271 (28.3%) 86 (29.4%) 185 (27.8%)  
 Lung disease 38 (4.0%) 14 (4.8%) 24 (3.6%)  
 Cerebrovascular accident 64 (6.7%) 20 (6.8%) 44 (6.6%)  
 Heart disease 25 (2.6%) 8 (2.7%) 17 (2.6%)  
 Liver cirrhosis 9 (0.9%) 4 (1.4%) 5 (0.7%)  
 Renal disease 15 (1.6%) 4 (1.4%) 11 (1.7%)  
Charlson Comorbidity Index     0.065
 0 243 (24.4%) 62 (21.1%) 181 (27.2%)  
 1–2 465 (48.5%) 147 (50.2%) 318 (47.8%)  
 3–6 250 (26.1%) 84 (28.7%) 166 (25.0%)  
Type of operation     0.063
 Laparoscopy 102 (10.6%) 23 (7.8%) 79 (11.9%)  
 Open 856 (89.4%) 270 (92.2%) 586 (88.1%)  
Type of gastrectomy     0.007
 Distal gastrectomy 549 (57.2%) 149 (50.9%) 400 (60.2%)  
 Total gastrectomy 409 (42.8%) 144 (49.1%) 265 (39.8%)  
Extent of lymphadenectomy     0.934
 D1 20 (2.0%) 6 (2.0%) 14 (2.1%)  
 D1 plus 241 (25.2%) 77 (26.3%) 164 (24.7%)  
 D2 697 (72.8%) 210 (71.7%) 487 (73.2%)  
TNM stagea     <  0.001
 2A 199 (20.8%) 26 (8.9%) 173 (26.0%)  
 2B 237 (24.7%) 61 (20.8%) 176 (26.5%)  
 3A 194 (20.3%) 47 (16.0%) 147 (22.1%)  
 3B 194 (20.3%) 80 (27.3%) 114 (17.1%)  
 3C 134 (14.0%) 79 (27.0%) 55 (8.3%)  
  1. aTNM stage was based on the American Joint Committee on Cancer 7th edition